

driven discovery as a powerful tool to elucidate biological processes and better characterize the health and health consequences of all people. This plan also fosters ethical use of new methodologies arising from artificial intelligence and machine learning.

The updated Strategic Plan will accomplish five overarching goals:

- *Goal 1:* Improve Capabilities to Sustain the NIH Policy for Data Management and Sharing
- *Goal 2:* Develop Programs to Enhance Human Derived Data for Research
- *Goal 3:* Provide New Opportunities in Software, Computational Methods, and Artificial Intelligence
- *Goal 4:* Support for a Federated Biomedical Research Data Infrastructure
- *Goal 5:* Strengthen a Broad Community in Data Science

The complete draft plan is available at: <https://datascience.nih.gov/sites/default/files/NIH-STRATEGIC-PLAN-FOR-DATA-SCIENCE-2023-2028-final-draft.pdf>.

Information Requested

NIH is requesting public comment throughout the scientific research community and members of the general public for the updated NIH Strategic Plan for Data Science. NIH encourages organizations (e.g., patient advocacy groups, professional organizations) to submit a single response reflective of the views of the organization or membership as a whole.

Response to this RFI is voluntary. Respondents are free to address any or all topics listed below, as well as other relevant topics, for NIH's consideration. If you choose to provide NIH with this information, NIH will not share your name and contact information outside of NIH unless required by law.

The NIH seeks comments on any of the following topics:

- The appropriateness of the goals of the plan, the strategies and implementation tactics proposed to achieve them; including potential benefits, drawbacks or challenges.
- Opportunities for NIH to partner to achieve these goals.
- Emerging research needs and opportunities that should be added to the plan.
- Any other topic the respondent feels is relevant for NIH to consider in developing this strategic plan.

This RFI is for planning purposes only and should not be construed as a solicitation for applications or proposals, or as an obligation in any way on the part of the United States federal government. The federal

government will not pay for the preparation of any information submitted or for the government's use. Additionally, the government cannot guarantee the confidentiality of the information provided.

Dated: January 6, 2024.

Lawrence A. Tabak,

Principal Deputy Director, National Institutes of Health.

[FR Doc. 2024-00696 Filed 1-12-24; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting of the National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel; Brain Initiative TMM RFA Review.

Date: February 15, 2024.

Time: 10:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Democracy II, Suite 920, 6707 Democracy Blvd., Bethesda, MD 20817 (Virtual Meeting).

Contact Person: Alexander O. Komendantov, Ph.D., MS, Scientific Review Officer, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, 6707 Democracy Blvd., Bethesda, MD 20892, (301) 451-3397, alexander.komendantov@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health.)

Dated: January 9, 2024.

Victoria E. Townsend,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024-00627 Filed 1-12-24; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel, March 06, 2024, 10:00 a.m. to March 06, 2024, 04:00 p.m., National Institutes of Health, NIDDK, Democracy II, Suite 7000A, 6707 Democracy Boulevard, Bethesda, MD 20892 which was published in the **Federal Register** on November 07, 2023, 88 FR 77326.

This meeting notice is amended to change the date from 3/06/2024 to 3/05/2024. The meeting is closed to the public.

Dated: January 9, 2024.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024-00626 Filed 1-12-24; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HOMELAND SECURITY

U.S. Customs and Border Protection

Test Concerning Entry of Section 321 Low-Value Shipments Through the Automated Commercial Environment (ACE) (Also Known as Entry Type 86); Republication With Modifications

AGENCY: U.S. Customs and Border Protection, Department of Homeland Security.

ACTION: General notice.

SUMMARY: This document republishes with modifications and supersedes a U.S. Customs and Border Protection (CBP) notice published in the **Federal Register** on August 13, 2019, announcing a test to allow certain low-value shipments, including those shipments subject to Partner Government Agency (PGA) data requirements, to be entered by filing a new type of informal entry electronically in the Automated Commercial Environment (ACE). The test is known as the ACE Entry Type 86 Test. This document modifies the ACE Entry Type 86 Test to clarify the waiver of certain regulations and consequences of misconduct by test participants. In addition, this document makes minor technical changes to the original notice. **DATES:** The ACE Entry Type 86 Test commenced September 28, 2019, and